Agios Pharmaceuticals, Inc. (AGIO) is a Biotechnology company in the Healthcare sector, currently trading at $33.30. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is AGIO = $42 (+24.6% upside).
Valuation: AGIO trades at a trailing Price-to-Earnings (P/E) of -4.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.21.
Financials: revenue is $54M, +57.5%/yr average growth. Net income is $413M (loss), growing at -80.7%/yr. Net profit margin is -764% (negative). Gross margin is 88.3% (+0.3 pp trend).
Balance sheet: total debt is $62M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 11.46 (strong liquidity). Debt-to-assets is 4.8%. Total assets: $1.3B.
Analyst outlook: 22 / 29 analysts rate AGIO as buy (76%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 100/100 (Pass), Moat 58/100 (Partial), Future 79/100 (Pass), Income 10/100 (Fail).
